Clinical Trial Update: Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and tolerability of an MVA-based vaccine expressing brachyury and T-cell costimulatory molecules (MVA-Brachyury-TRICOM) in cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Tumors

Drugs mentioned

• MVA-Brachyury-TRICOM (Modified Vaccinia Ankara-based vaccine expressing brachyury and T-cell costimulatory molecules)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Cancer, Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-01-26